PeptoBrush Enables Sustained Release of Auger Radiotherapeutic [(125)I]Iododeoxyuridine for Glioblastoma Treatment.
In this study, we report the development of a novel nanocarrier ("PeptoBrush") for the sustained release of the Auger-emitting radiotherapeutic agent [125I]iododeoxyuridine ([125I]IUdR).
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Glioma
- Glioblastoma Clinical Trials for New Treatments
- Clinical trial links oncolytic immunoactivation to survival in glioblastoma
- Treating the invisible target: treatment planning targeting the microscopic tumor spread in gliomas
- EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma